Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
A blood-based biomarker of Alzheimer's disease (AD) progression could be instrumental in targeting asymptomatic individuals for treatment early in the disease process.
-
PET imaging with (11)C-labeled Pittsburgh Compound-B ((11)C-PIB) helps discriminate Alzheimer disease (AD) from frontotemporal lobar degeneration (FTLD).
-
A panel of possible CSF biomarkers for AD has been identified using proteomic methods.
-
Mean +/- SD CSF NFL levels were increased in patients with FTD (1442 +/- 1183 pg/mL; p < 0.05) and LAD (1006 +/- 727 pg/mL; p < 0.001) compared with control subjects (241 +/- 166 pg/mL) and in LAD compared with EAD (498 +/- 236 pg/mL; p < 0.05), and tended to be increased in FTD compared with EAD.
-
Sleep disruption, nightly restlessness, sundowning, and other circadian disturbances are frequently seen in Alzheimer's disease (AD) patients.
-
Conductance to outflow of CSF was measured in a prospective study of 80 patients with normal pressure hydrocephalus.
-
In 14 of the 15 suspected HAb cases, HBT treatment greatly reduced measured p-tau217 concentrations. and in one of three specimens selected for further investigation, reduced Aβ42 concentrations PEG precipitation in the three selected samples also reduced p-tau217 concentrations, while serial dilution yielded mixed effects.
-
Plasma biomarkers were associated with comorbidities and metabolites such as estimated glomerular filtration rate, homocysteine, and high-density lipoprotein.
-
Participants rated the materials highly regarding value and comprehension.
-
46/100
Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) refers to the aberrant accumulation of TDP-43 in the brains of ageing individuals either in isolation or in combination with neurodegenerative disease.
-
Compared to ADSAA-, ADSAA+ showed putamen SRP hypermetabolism and middle occipital gyrus (MOG) SUVR hypometabolism.
-
Alpha-synuclein (α-syn) deposits are common in around half of the Alzheimer's disease (AD) cases.
-
As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development.
-
The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration.
-
Elevated BMI/BV associated with lower BBM concentrations, especially for p-Tau217 and NfL, independent of brain amyloid burden.
-
Tau hyperphosphorylation, a key neuropathological feature of tauopathies such as Alzheimer's disease (AD), also occurs physiologically during mammalian hibernation and is fully reversed upon arousal, offering a unique translational model to study tau metabolism.
-
Within each tracer, GMM-derived amyloid negative (A-) CL distributions were similar across cohorts.
-
AD mice showed early decreases in NVC and bilateral connectivity (BC) in motor and cingulate cortex, and hypoconnectivity within the sensory-motor network.
-
As the most prevalent form of dementia, Alzheimer's disease (AD) represents a major public health challenge.
-
This scientific commentary refers to ‘A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests’ by Warmenhoven et al. (https://doi.org/10.1093/brain/awae346) and ‘Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison’ by Pilotto et al. (https://doi.org/10.1093/brain/awae368).
-
46/100
Models including plasma biomarkers yielded the most accurate predictions of tau-PET burden (best model: R-squared = 0.66-0.69), with especially high contribution from plasma phosphorylated tau-217 (p-tau217).
-
Gantenerumab reduced amyloid PET load, CSF biomarkers of amyloid beta (Aβ)40, total tau (t-tau), phosphorylated tau 181 (p-tau181), neurogranin, S100 calcium-binding protein B (S100B), neurofilament light (NfL), alpha-synuclein (α-syn), neuronal pentraxin-2 (NPTX2), and plasma biomarkers of t-tau, p-tau181, p-tau217, and glial fibrillary acidic protein (GFAP) while increasing plasma Aβ40, Aβ42. vMRI showed increased reduction in whole brain volume and increased ventricular expansion, while hippocampal volume was unaffected.
-
The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community.
-
Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy body disease (LBD), occurring in approximately half of all cases.
-
An AD diagnostic accuracy of 91.9% was achieved by using a hybrid meta-ROI consisting of thicknesses of entorhinal and middle temporal cortices, and the volumes of the hippocampus and inferior lateral ventricles.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- [18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
- Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia
- The Role of Tau Imaging in Parkinsonian Disorders
- Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid
- Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression
- Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
- Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome
- Ocular indicators of Alzheimer's: exploring disease in the retina
- Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy
- Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders